Section Arrow
Quote
BMRN.NASDAQ
- BioMarin Pharmaceutical
Quotes are at least 15-min delayed:2026/01/01 21:43 EST
Regular Hours
Last
 59.43
+0.44 (+0.75%)
Day High 
59.715 
Prev. Close
58.99 
1-M High
63.89 
Volume 
1.40M 
Bid
58
Ask
61.63
Day Low
58.44 
Open
58.8 
1-M Low
50.9 
Market Cap 
11.33B 
Currency 美元 
P/E 21.93 
%Yield -- 
10-SMA 57.62 
20-SMA 55.54 
50-SMA 54.47 
52-W High 73.51 
52-W Low 50.76 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.69/5.31
Enterprise Value
11.93B
Balance Sheet
Book Value Per Share
31.53
Cash Flow
Cash Flow Yield
0.08
Income Statement
Total Revenue
2.85B
Operating Revenue Per Share
12.03
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4167+0.0462+12.47%-- 
OTLKOutlook Therapeutics1.58-0.285-15.28%0.58PE
VNDAVanda Pharmaceuticals8.82+1.79+25.46%126.25PE
SLSSELLAS Life Sciences Group3.77+0.46+13.90%-- 
FBLGFibroBiologics0.2249-0.017-7.03%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.